Research progress in molecular targets of triple-negative breast cancer
LUO Jiadi;FAN Songqing;Department of Pathology, Second Xiangya Hospital, Central South University;
Triple-negative breast cancer(TNBC) without estrogen receptor, progestrogen receptor and HER-2 expression, represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents. Therefore biomarkers predictive of response to treatment are of great importance in TNBC. This review evaluates biomarkers predictive of response to neoadjuvant chemotherapy and targeted therapies in TNBC, in order to increase opportunities to improve patient outcomes.